Warfarin Anticoagulation Therapy in Caribbean Hispanics of Puerto Rico: A Candidate Gene Association Study

Karla Claudio-Campos1, Aurora Labastida2, Alga Ramos3

  • 1Department of Pharmacology and Toxicology, School of Medicine, University of Puerto RicoSan Juan, PR, United States.

Insights

New genetic variants, including CYP2C9 rs2860905, improve warfarin dose prediction in Caribbean Hispanics. This study identifies key genetic factors for personalized warfarin therapy in diverse populations.

Area of Science:

  • Pharmacogenomics
  • Human Genetics
  • Cardiovascular Medicine

Background:

  • Existing warfarin dosing algorithms explain ~50% of dose variance, with limited performance in non-Caucasian populations due to overlooked ethno-specific variants.
  • Warfarin pharmacogenetics is crucial for personalized medicine, but knowledge gaps exist for diverse ethnic groups.

Purpose of the Study:

  • To identify genetic polymorphisms influencing warfarin dose variability in Caribbean Hispanics from Puerto Rico.
  • To characterize the genomic structure and admixture patterns of the study cohort.

Main Methods:

  • Next-Generation Sequencing of CYP2C9 and VKORC1, and genotyping via DMET® Plus Assay.
  • Case-control association analysis using the Extreme Discordant Phenotype approach.
  • Genomic structure and admixture analysis.

Main Results:

  • The CYP2C9 variant rs2860905 showed a stronger association with warfarin sensitivity than CYP2C9*2 and CYP2C9*3.
  • Polymorphisms in CES2 and ABCB1 were linked to warfarin resistance.
  • A regression model incorporating rs2860905, other genetic factors, and non-genetic factors improved warfarin dose prediction (R² = 0.63).

Conclusions:

  • Novel genetic variants, particularly CYP2C9 rs2860905, enhance the predictability of warfarin dosing in Caribbean Hispanics.
  • The Puerto Rican cohort exhibits a tri-hybrid admixture pattern with significant Native American ancestry.
  • Findings highlight the need for population-specific genetic data in pharmacogenomic studies for warfarin therapy.

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.1K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
53
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.6K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
63
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
16.0K
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
59